Home

We believe that everybody should have access to effective and high-quality healthcare.

Our innovative technology enables patient-friendly ultrasound procedures.

Our easy-to-use products ensure reliable diagnostic and therapeutic microbubbles for effective and high-quality healthcare.

Products

Solstice Pharma provides diagnostic and therapeutic solutions to healthcare professionals. The key part of our portfolio is Harmono-T®, the first ultrasound contrast agent comprising of uniform microbubbles. This is supported by our Activation Station, which activates Harmono-T® at the bedside of the patient.

News

Launch of the BbubbleCard Project

Solstice Pharmaceuticals obtains GMP Manufacturing License for Clinical Trials

Solstice Pharmaceuticals, a leading innovator in diagnostic and therapeutic ultrasound applications, is proud to announce that we have successfully obtained our Good Manufacturing Practice (GMP) license for the manufacturing of investigational medicinal products (IMP) for our up coming clinical trials. This significant milestone marks a pivotal moment for our company and the dedicated team involved in this achievement.

Meet Solstice Pharmaceuticals at ECIO 2025 in Rotterdam

Solstice Pharmaceuticals, a leading innovator in diagnostic and therapeutic ultrasound applications, proudly announces its participation in The European Conference on Interventional Oncology (ECIO) from 13^th to 16^th April 2025, in Rotterdam, The Netherlands. The Solstice Pharmaceuticals team is thrilled to join this event and to engage with key clinical, research, and industry partners.

Solstice Pharmaceuticals to sponsor and participate in the 29th European Symposium on Ultrasound Contrast Imaging in Rotterdam

Solstice Pharmaceuticals, a leading innovator in diagnostic and therapeutic ultrasound applications, proudly announces its participation in the 29th European Symposium on Ultrasound Contrast Imaging.

Solstice Pharmaceuticals Completes Cleanroom Facilities for Clinical Trial Manufacturing of Monodisperse Microbubbles

Solstice Pharmaceuticals is proud to announce the completion of our state-of-the-art cleanroom facilities for the clinical trial manufacturing of our cartridge system for monodisperse microbubbles. This is a significant milestone for our company and for the clinical translation of our cutting-edge technology.

Solstice Pharma on the move – New HQ Announcement

We are delighted to announce that we are moving as per 1^st August 2022 to our new HQ and thereby tripling the size of our office and cleanroom & manufacturing facilities.

Solstice Awarded Innovatiekrediet funding by the Dutch government

20th January 2022 – Solstice Pharmaceuticals is pleased to announce we have been granted Innovatiekrediet, the investment matching fund of the Dutch government, which is awarded through the Netherlands Enterprise Agency (RVO).

Jan Sigger joins Solstice’s Board of Directors

26^th July 2021 – Jan Sigger, founder and former CEO of Quirem Medical, has joined the team at Solstice Pharmaceuticals as Chairman of the Board of Directors to provide the board with leadership and to harness the talents and energy contributed by each of the individual directors.

Solstice Awarded High Tech Fund support

21^st July 2021 – We are pleased to announce that we have been granted support from the High Tech Fund. This financial support will enable us to establish our GMP pilot line for our UCA cartridges and accelerate our product development and clinical trajectory.

Parker Labs Leads Investment in Solstice Pharma’s Innovative Ultrasound Contrast Agent

2^nd July 2021 – Solstice Pharmaceuticals has successfully completed its latest round of funding to further the clinical development of its innovative ultrasound contrast agent (UCA). The first-of-its-kind contrast agent uses unique microbubble technology that dramatically enhances image contrast, improves diagnostic accuracy and makes ultrasound more widely applicable for a wide range of diagnostic and therapeutic applications.